Can-Fite BioPharma (NYSE:CANF) Now Covered by StockNews.com

Analysts at StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report issued on Thursday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Can-Fite BioPharma in a research note on Thursday, May 9th.

Can-Fite BioPharma Trading Up 6.4 %

Can-Fite BioPharma stock opened at $3.47 on Thursday. The firm has a 50 day moving average of $2.57 and a 200 day moving average of $2.27. The firm has a market capitalization of $12.28 million, a price-to-earnings ratio of -1.94 and a beta of 1.45. Can-Fite BioPharma has a 12-month low of $1.81 and a 12-month high of $4.48.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. Schechter Investment Advisors LLC purchased a new stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 20,077 shares of the company’s stock, valued at approximately $44,000. Schechter Investment Advisors LLC owned 0.57% of Can-Fite BioPharma at the end of the most recent quarter. 21.00% of the stock is owned by institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.